Amphastar Pharmaceuticals
AMPH
168 hedge funds and large institutions have $678M invested in Amphastar Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 62 increasing their positions, 48 reducing their positions, and 7 closing their positions.
443% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 7
29% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 48
28% more capital invested
Capital invested by funds: $530M → $678M (+$148M)
21% more funds holding
Funds holding: 139 → 168 (+29)
2.81% more ownership
Funds ownership: 58.15% → 60.96% (+2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$7.15M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$4.45M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.37M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$4.3M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$4.97M |
| 2 |
Millennium Management
New York
|
-$2.53M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$1.65M |
| 4 |
JP Morgan Chase
New York
|
-$1.29M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.11M |
AMPH Hedge Fund Activity: Q4 2021 in Review
168 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2021, worth a combined $678M — up 28% from $530M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AMPH positions and 7 closed out — a net gain of 31 holders — while 62 added to existing stakes and 48 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $7.15M. The largest seller was Wells Fargo, cutting an estimated $4.97M.
- 168 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2021, up from 139 in Q3 2021.
- Funds reported $678M of Amphastar Pharmaceuticals stock for Q4 2021, up 28% quarter-over-quarter.
- 38 funds opened new Amphastar Pharmaceuticals positions in Q4 2021 and 7 closed out, a net change of +31 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2021 was Assenagon Asset Management, an estimated $7.15M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2021 was Wells Fargo, an estimated $4.97M sold.
Based on aggregated 13F filings for Q4 2021.